Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.49 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.49 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.49 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.49 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.49 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3793149 | 0.83 | PDK1 (0.58) | MEN1KMT2ASMN1; SMN2RORCALDH1A1 | |
| SCHEMBL2312129 | 0.81 | ALDH1A1 (0.69) | MEN1KMT2ASMN1; SMN2RORCALDH1A1 | |
| SCHEMBL6514545 | 0.80 | CA2 (0.56) | SMN1; SMN2RORCALDH1A1ATAD2CECR2 | |
| SCHEMBL15544947 | 0.79 | MAPK1 (0.51) | MEN1KMT2ASMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL2314802 | 0.78 | ALDH1A1 (0.51) | SMN1; SMN2RORCALDH1A1ATAD2CECR2 | |
| SCHEMBL15545458 | 0.76 | ALDH1A1 (0.53) | SMN1; SMN2MAPK1ALDH1A1ABCC9ABCC8 | |
| SCHEMBL28875490 | 0.75 | KDR (0.57) | MEN1KMT2ASMN1; SMN2RORCALDH1A1 | |
| SCHEMBL2787734 | 0.75 | NR1H4 (0.47) | MEN1KMT2ASMN1; SMN2ALDH1A1ABCC9 | |
| SCHEMBL15544994 | 0.75 | ABCC9 (0.39) | MEN1KMT2ASMN1; SMN2MAPK1ABCC9 | |
| SCHEMBL15544997 | 0.75 | ABCC9 (0.39) | MEN1KMT2ASMN1; SMN2MAPK1ABCC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104428289-B | As the triazole compounds of antivirotic | 弗·哈夫曼-拉罗切有限公司 | 2017-06-23 | — | — | CN | disclosed |
| EP-2870143-B1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| EP-2870143-B1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| US-20150307461-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150307461-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150307461-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-29 | — | — | US | disclosed |
| EP-2870143-A1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | F. Hoffmann-La Roche AG (CH) | 2015-05-13 | — | — | EP | disclosed |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2014-01-09 | — | — | US | disclosed |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2014-01-09 | — | — | US | disclosed |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2014-01-09 | — | — | US | disclosed |
| WO-2014006066-A1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307461-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | MEN1 4686/4885KMT2A 4470/4885SMN1; SMN2 2853/4885 |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | MEN1 4686/4885KMT2A 4470/4885SMN1; SMN2 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.